Literature DB >> 16682536

Neuropathologic features of amnestic mild cognitive impairment.

Ronald C Petersen1, Joseph E Parisi, Dennis W Dickson, Kris A Johnson, David S Knopman, Bradley F Boeve, Gregory A Jicha, Robert J Ivnik, Glenn E Smith, Eric G Tangalos, Heiko Braak, Emre Kokmen.   

Abstract

BACKGROUND: The neuropathologic substrate of amnestic mild cognitive impairment (aMCI) is not known.
OBJECTIVE: To determine the neuropathologic features of patients who died while their clinical classification was aMCI.
DESIGN: Cohort study.
SETTING: Community based. PARTICIPANTS: Sixty-six individuals, including 15 who had memory impairment beyond that allowed for aging but who were not demented, were studied along with 28 clinically healthy individuals and 23 patients with probable Alzheimer disease (AD) for comparison. MAIN OUTCOME MEASURES: Standard neuropathologic techniques and classification according to Khachaturian, Consortium to Establish a Registry for Alzheimer Disease, and National Institute on Aging-Reagan criteria were used to analyze autopsy tissue from 15 individuals who died while their clinical diagnosis was aMCI. For comparison, autopsy data on age-matched groups of clinically healthy individuals and patients with probable AD were analyzed.
RESULTS: Most patients with aMCI did not meet the neuropathologic criteria for AD, but their pathologic findings suggest a transitional state of evolving AD. All the patients with aMCI had pathologic findings involving medial temporal lobe structures, likely accounting for their memory impairment. In addition, there were many concomitant pathologic abnormalities, including argyrophilic grain disease, hippocampal sclerosis, and vascular lesions.
CONCLUSIONS: The neuropathologic features of aMCI matched the clinical features and seemed to be intermediate between the neurofibrillary changes of aging and the pathologic features of very early AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682536     DOI: 10.1001/archneur.63.5.665

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  219 in total

1.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 3.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

4.  Neurodegenerative basis of age-related cognitive decline.

Authors:  R S Wilson; S E Leurgans; P A Boyle; J A Schneider; D A Bennett
Journal:  Neurology       Date:  2010-09-15       Impact factor: 9.910

5.  Performance-based measures of everyday function in mild cognitive impairment.

Authors:  Terry E Goldberg; Jeremy Koppel; Lynda Keehlisen; Erica Christen; Ute Dreses-Werringloer; Concepcion Conejero-Goldberg; Marc L Gordon; Peter Davies
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

6.  VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2010-11       Impact factor: 3.444

7.  Effects of age on the glucose metabolic changes in mild cognitive impairment.

Authors:  Kejal Kantarci; M L Senjem; V J Lowe; H J Wiste; S D Weigand; B J Kemp; A R Frank; M M Shiung; B F Boeve; D S Knopman; R C Petersen; C R Jack
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

9.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

10.  Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.

Authors:  Peng Yu; Jia Sun; Robin Wolz; Diane Stephenson; James Brewer; Nick C Fox; Patricia E Cole; Clifford R Jack; Derek L G Hill; Adam J Schwarz
Journal:  Neurobiol Aging       Date:  2013-10-03       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.